These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27764168)

  • 1. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
    Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
    PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
    Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
    Yokoyama K; Kurita N; Fukuma S; Akizawa T; Fukagawa M; Onishi Y; Kurokawa K; Fukuhara S
    Nephrol Dial Transplant; 2017 Mar; 32(3):534-541. PubMed ID: 26945054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
    Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
    de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
    Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
    Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
    Oshiro Y; Tanaka H; Okimoto N
    Clin Exp Nephrol; 2011 Aug; 15(4):607-10. PubMed ID: 21455660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
    Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA
    BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.